2017-03-07,ArQule Reports Fourth Quarter And Full Year 2016 Financial Results
2017-02-24,ArQule To Report Fourth Quarter And Year End 2016 Financial Results On March 7, 2017
2017-02-17,Daiichi Sankyo And ArQule Announce The Completion Of The METIV-HCC Phase 3 Study Of Tivantinib In Second-Line Treatment Of MET-Overexpressing Hepatocellular Carcinoma
2017-02-08,ArQule To Present At The Leerink Partners 6th Annual Global Healthcare Conference On February 15, 2017
2016-12-04,Data On Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition Of Wild Type And C481S Mutant BTK And Superiority To Ibrutinib In TCL1 Mouse Model Presented At The American Society Of Hematology Annual Meeting
2016-12-03,Preclinical Data On Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness In The Treatment Of Sickle Cell Disease Presented At The American Society Of Hematology Annual Meeting
2016-11-07,ArQule Reports Third Quarter 2016 Financial Results
2016-11-03,Advancements In ArQule's Proprietary Pipeline To Be Highlighted At The 2016 American Society Of Hematology Annual Meeting
2016-10-24,ArQule To Report Third Quarter 2016 Financial Results On November 7, 2016
2016-09-21,ArQule To Present At The Leerink Partners Rare Disease And Immuno-Oncology Roundtable On September 28, 2016
2016-09-15,ArQule Announces Publication Of Manuscript Highlighting Preclinical Activity Of FGFR Inhibitor, ARQ 087, In Peer Reviewed Journal
2016-08-03,ArQule Reports Second Quarter 2016 Financial Results
2016-07-20,ArQule To Report Second Quarter 2016 Financial Results On August 3, 2016
2016-07-18,ArQule Presents Preclinical Data For ARQ 531, A Proprietary Reversible Inhibitor Of Wild Type And Mutant BTK, At The 2016 Pan Pacific Lymphoma Conference
2016-07-05,ArQule To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference On July 12, 2016
2016-06-30,ArQule Presents Preliminary Clinical Data For ARQ 087 Demonstrating Evidence Of Anticancer Activity In Intrahepatic Cholangiocarcinoma At The ESMO 18th World Congress On Gastrointestinal Cancer
2016-06-23,ArQule To Present Preliminary Phase 1/2 Data For FGFR Inhibitor, ARQ 087, In Intrahepatic Cholangiocarcinoma At The ESMO 18th World Congress On Gastrointestinal Cancer
2016-05-04,ArQule Reports First Quarter 2016 Financial Results
2016-04-20,ArQule To Report First Quarter 2016 Financial Results On May 4, 2016
2016-04-05,ArQule To Present At The 15th Annual Needham Healthcare Conference On April 12, 2016
2016-03-22,Daiichi Sankyo And ArQule Announce Continuation Of METIV-HCC Phase 3 Study Of Tivantinib In Second-Line Hepatocellular Carcinoma
2016-02-29,ArQule Reports Fourth Quarter And Full Year 2015 Financial Results
2016-02-29,ArQule Announces $15.3 Million Registered Direct Offering Of Common Stock
2016-02-15,ArQule To Report Fourth Quarter And Full Year 2015 Financial Results On February 29, 2016
2016-02-04,ArQule To Present At Upcoming Investor Conferences
2016-01-28,ArQule Provides Proprietary Pipeline Update For AKT Inhibitors
2016-01-25,ArQule Presents Clinical Biomarker Data From Phase 2 Study And Ongoing Phase 3 METIV-HCC Study Of Tivantinib In Second-Line Hepatocellular Carcinoma At The 2016 Gastrointestinal Cancers Symposium
2015-12-21,Insider Trading Alert - SUMR, CVO And ARQL Traded By Insiders
2015-12-18,Insider Trading Alert - ARQL, MTSC And PFNX Traded By Insiders
2015-12-17,Insider Trading Alert - SAVE, ARQL And THST Traded By Insiders
2015-12-15,Insider Trading Alert - ORM, OLBK And ARQL Traded By Insiders
2015-12-15,ArQule Announces Orphan Drug Designation In Cholangiocarcinoma And Clinical Update For ARQ 087
2015-12-14,Insider Trading Alert - TIPT, RDNT And ARQL Traded By Insiders
2015-12-10,ArQule And Daiichi Sankyo Announce Completion Of Accrual In METIV-HCC Phase 3 Trial Of Tivantinib For Second-Line Hepatocellular Carcinoma
2015-11-17,ArQule And The National Human Genome Research Institute Of The National Institutes Of Health Announce Enrollment Of First Patient In The Phase 1 Proteus Syndrome Trial With ARQ 092
2015-11-09,UPDATE -- ArQule Presents Data On Tivantinib And Proprietary Pipeline At AACR-NCI-EORTC Conference
2015-11-09,ArQule Presents Data On Tivantinib And Propietary Pipeline At AACR-NCI-EORTC Conference
2015-11-04,ArQule Reports Third Quarter 2015 Financial Results
2015-10-27,ArQule To Present Data On Tivantinib, ARQ 087, ARQ 092, And ARQ 751 At AACR-NCI-EORTC Conference
2015-10-21,ArQule To Report Third Quarter 2015 Financial Results On November 4, 2015
2015-10-15,ArQule Announces Publication Of Manuscript Highlighting Activity Of AKT Inhibitor ARQ 092 And Next Generation AKT Inhibitor ARQ 751 In Oncology
2015-09-28,ArQule Presents Results From Phase 1b Expansion Study Of ARQ 092 At The 2015 European Cancer Conference
2015-09-25,ArQule To Present At Leerink Partners 4th Annual Rare Disease Roundtable On September 30, 2015
2015-09-08,ArQule Presents Additional Clinical Biomarker Data From Phase 2 Study Of Tivantinib In Hepatocellular Carcinoma At International Liver Cancer Association Conference
2015-08-05,ArQule Reports Second Quarter 2015 Financial Results
2015-07-29,ArQule To Report Second Quarter 2015 Financial Results On August 5, 2015
2015-07-06,ArQule Announces Interim Phase 2 Study Results For Tivantinib In Combination With Cetuximab In Patients With MET-High, KRAS Wild Type Colorectal Cancer Presented At ESMO World Congress On Gastrointestinal Cancer 2015
2015-06-01,ArQule Appoints Robert J. Weiskopf As Chief Financial Officer
2015-05-29,ArQule Announces Data Presentations With Tivantinib And ARQ 087 To Be Featured At ASCO 2015
2015-05-27,ArQule, Inc. To Present At Jefferies 2015 Global Healthcare Conference
2015-05-06,ArQule Reports First Quarter 2015 Financial Results
2015-05-05,ArQule And Beryllium Announce Collaborative Research And Development Agreement
2015-04-29,ArQule To Report First Quarter 2015 Financial Results On May 6, 2015
2015-04-21,ArQule Announces Data Presentations With ARQ 087, Inhibitor Of FGFR, At AACR
2015-04-07,ArQule, Inc. To Present At 14th Annual Needham Healthcare Conference
2015-03-25,Interesting ARQL Call Options For May 15th
2015-03-04,ArQule Reports Fiscal 2014 Year End And Fourth Quarter Results
2015-02-25,ArQule To Report Fiscal 2014 Financial Results On March 4, 2015
2015-02-17,ArQule, Inc. To Present At 2015 RBC Capital Markets' Global Healthcare Conference
2015-02-04,ArQule, Inc. To Present At Leerink Global Healthcare Conference
2014-11-21,Insider Trading Alert - ITG, CDXS And ARQL Traded By Insiders
2014-11-13,ArQule Announces Data Presentations With Pipeline Products To Be Featured At 26th EORTC-NCI-AACR Symposium
2014-11-11,ArQule Announces Collaboration With NIH For Clinical Development Of ARQ 092 In Proteus Syndrome
2014-11-10,ArQule Announces Positive Top-Line Results Of NIH-Sponsored Phase 2 Trial Of Tivantinib In Prostate Cancer
2014-11-10,ArQule Announces Third Quarter Fiscal 2014 Results
2014-11-03,ArQule To Report Third Quarter 2014 Financial Results On November 10, 2014
2014-08-05,ArQule Reports Second Quarter 2014 Financial Results
2014-07-29,ArQule To Report Second Quarter 2014 Financial Results On August 5, 2014
2014-06-20,4 Biotech Stocks Under $10 to Watch for Breakout Trades
2014-05-30,ArQule Announces Data Presentations With Tivantinib To Be Featured At ASCO 2014
2014-05-29,ArQule To Present At Jefferies Global Healthcare Conference
2014-05-27,First Week of ARQL January 2015 Options Trading
2014-05-22,5 Stocks Under $10 Set to Soar
2014-05-16,3 Stocks Under $10 Making Big Moves
2014-05-12,Short Interest In ArQule Increases 18.7%
2014-05-07,ArQule Reports First Quarter 2014 Financial Results
2014-04-30,ArQule To Report First Quarter 2014 Financial Results On May 7, 2014
2014-04-02,ArQule, Inc. To Present At Needham 13th Annual Healthcare Conference
2014-03-20,ARQL: Insiders vs. Shorts
2014-03-05,ArQule Reports Fiscal 2013 Year End And Fourth Quarter Results
2014-02-26,ArQule To Report Fiscal 2013 Financial Results On March 5, 2014
2014-02-18,ArQule, Inc. To Present At RBC Capital Markets Healthcare Conference
2014-02-05,ArQule, Inc. To Present At Leerink Swann Global Healthcare Conference
2014-02-04,First Week of March 22nd Options Trading For ArQule (ARQL)
2014-02-04,ArQule Announces Commencement Of Phase 3 Clinical Trial With Tivantinib In Hepatocellular Carcinoma By Partner Kyowa Hakko Kirin In Japan
2014-01-17,First Week of February 22nd Options Trading For ArQule (ARQL)
2014-01-16,ArQule Provides Updates On Clinical Trials In Hepatocellular Carcinoma And Non-Small Cell Lung Cancer With Tivantinib
2014-01-13,Short Interest Declines 16.5% For ARQL
2013-11-07,ArQule Announces Third Quarter Fiscal 2013 Results
2013-10-31,ArQule To Report Third Quarter 2013 Financial Results On November 7, 2013
2013-10-25,ArQule Stock Sees Short Interest Increase 18%
2013-09-30,Data Presented At European Cancer Congress Suggest Clinical Benefit Of Tivantinib In Patients With MET High Non-Squamous Non-Small Cell Lung Cancer
2013-08-12,ArQule Stock Sees Short Interest Decrease By 17%
2013-07-30,ArQule Reports Second Quarter 2013 Financial Results
2013-07-23,ArQule To Report Second Quarter 2013 Financial Results On July 30, 2013
2013-07-05,Commit To Purchase ArQule $2.50, Earn 29.6% Annualized
2013-07-03,ArQule, Inc. To Present At JMP Securities Annual Healthcare Conference
2013-05-15,10 ASCO '13 Abstracts You Can Read Right Now
2013-03-14,ArQule Reports Fiscal 2012 Year End And Fourth Quarter Results
2013-03-07,ArQule To Report Fiscal 2012 Financial Results On March 14, 2013
2013-02-27,ArQule, Inc. To Present At Cowen And Company 33rd Annual Health Care Conference
2013-02-19,ArQule, Inc. To Present At RBC Capital Markets Global Healthcare Conference
2013-02-07,ArQule, Inc. To Present At Leerink Swann Global Healthcare Conference
2013-01-31,Daiichi Sankyo And ArQule Enroll First Hepatocellular Carcinoma Patient Into Global Phase 3 Trial For Tivantinib
2013-01-11,Daiichi Sankyo And ArQule Announce Top-Line Results Of Phase 2 Trial With Tivantinib In Colorectal Cancer
2012-12-13,ArQule Enrolls First Patient In Phase 1 Trial With ARQ 087, An FGFR Inhibitor
2012-12-05,ArQule, Inc. To Present At Oppenheimer Healthcare Conference
2012-11-30,5 Under-$10 Stocks Setting Up to Trade Higher
2012-11-07,ArQule, Inc. To Present At Lazard Healthcare Conference
2012-11-01,ArQule Announces Third Quarter Fiscal 2012 Results
2012-10-26,5 Stocks Poised for Breakouts
2012-10-25,ArQule To Report Third Quarter 2012 Financial Results On November 1, 2012
2012-10-16,ArQule And Daiichi Sankyo Reach Agreement With FDA On Special Protocol Assessment For Phase 3 Trial Of Tivantinib In Hepatocellular Carcinoma
2012-10-02,Dow Closes Lower; Nasdaq, S&P 500 Edge Up
2012-10-02,Arqule Shutters Lung Cancer Study Early Due to Futility
2012-10-02,ArQule And Daiichi Sankyo Announce Discontinuation Of Phase 3 MARQUEE Clinical Trial In Non-Small Cell Lung Cancer
2012-09-12,ArQule, Inc. To Present At UBS Global Life Sciences Conference
2012-08-30,ArQule, Inc. To Present At Upcoming Investment Conferences
2012-08-29,Arqule Shares Slide on Lung Cancer Drug Safety Concern
2012-08-02,ArQule Reports Second Quarter 2012 Financial Results
2012-07-26,ArQule To Report Second Quarter 2012 Financial Results On August 2, 2012
2012-07-06,ArQule, Inc. To Present At JMP Securities Annual Healthcare Conference
2012-06-02,ASCO 2012 Live Blog -- Saturday
2012-06-02,Positive Phase 2 Study Results For Tivantinib In Previously Treated Hepatocellular Carcinoma To Be Presented At ASCO
2012-05-31,ArQule, Inc. To Present At Jefferies 2012 Global Healthcare Conferences
2012-05-22,22 Biopharma Stocks With Breakout Potential in 2012
2012-05-18,ArQule And Daiichi Sankyo Announce Completion Of Patient Recruitment In Phase 3 Clinical Trial Of Tivantinib In Non-Small Cell Lung Cancer
2012-05-17,Positive Phase 2 Clinical Data With Tivantinib In Hepatocellular Carcinoma To Be Highlighted In Oral Presentation At 2012 Annual Meeting Of American Society Of Clinical Oncology
2012-05-17,ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update)
2012-05-16,ASCO '12 Abstract Dump: Cancer Stocks in Focus
2012-05-03,ArQule Reports First Quarter 2012 Financial Results
2012-04-26,ArQule To Report First Quarter 2012 Financial Results On May 3, 2012
2012-04-16,ArQule Announces Completion Of Common Stock Offering With Full Exercise Of Option To Purchase Additional Shares
2012-04-11,ArQule Prices Public Offering Of Common Stock
2012-04-10,ArQule Announces Proposed Public Offering
2012-04-03,3 Stocks Under $10 Moving Higher
2012-03-29,ArQule Announces Presentations At AACR 102nd Annual Meeting
2012-03-28,ArQule, Inc. To Present At 11th Annual Needham Healthcare Conference
2012-03-14,7 Cancer Drug Stocks to Know Right Now
2012-03-02,ArQule, Inc. To Present At Cowen And Company 32nd Annual Healthcare Conference
2012-03-01,ArQule Reports Fiscal 2011 Year End And Fourth Quarter Results
2012-02-23,ArQule To Report Fiscal 2011 Financial Results On March 1, 2012
2012-02-21,ArQule, Inc. To Present At RBC Capital Markets And Citi Conferences
2012-02-09,ArQule, Inc. To Present At Leerink Swann 2012 Global Healthcare Conference
2011-12-06,ArQule, Inc. To Present At Oppenheimer 22nd Annual Healthcare Conference
2011-11-15,Arqule Inc. Stock Downgraded (ARQL)
2011-11-10,ArQule Announces Third Quarter Fiscal 2011 Results
2011-11-10,Daiichi Sankyo To License ARQ 092 From ArQule, The First New Compound Resulting From The Companies&#8217; Joint AKIP Research Collaboration
2011-11-08,ArQule, Inc. To Present At Lazard Capital Markets 8th Annual Healthcare Conference
2011-11-03,ArQule To Report Third Quarter 2011 Financial Results On November 10, 2011
2011-09-12,ArQule, Inc. To Present At UBS Global Life Sciences Conference
2011-09-01,ArQule, Inc. To Present At Stifel Nicolaus 2011 Global Healthcare Conference
2011-08-04,ArQule Reports Second Quarter 2011 Financial Results
2011-07-28,ArQule To Report Second Quarter 2011 Financial Results On August 4, 2011
2011-06-03,ArQule, Inc. To Present At Jefferies 2011 Global Healthcare Conference
2011-05-31,ArQule Comments On Presentations At ASCO 2011
2011-05-10,Arqule Inc. Stock Upgraded (ARQL)
2011-05-05,ArQule Reports First Quarter 2011 Financial Results
2011-04-28,ArQule To Report First Quarter 2011 Financial Results On May 5, 2011
2011-04-28,ArQule, Inc. Announces Appointment Of Dr. Susan Kelley To Board Of Directors
2011-04-11,ArQule, Inc. To Present At Future Leaders In The Biotech Industry Conference
2011-03-31,ArQule Announces Presentations At AACR 102nd Annual Meeting
2011-03-30,ArQule, Inc. To Present At Needham And Leerink Swann Conferences
2011-03-01,ArQule Reports Fiscal 2010 Year End And Fourth Quarter Results
2011-02-28,ArQule, Inc. Announces Departure Of Board Member
2011-02-23,ArQule, Inc. To Present At Citi And Cowen Investment Conferences
2011-02-22,ArQule To Report Fiscal 2010 Financial Results On March 1, 2011
2011-02-07,ArQule, Inc. To Present At 13th Annual BIO CEO And Investor Conference
2011-01-25,ArQule Announces Completion Of Common Stock Offering With Full Exercise Of Overallotment Option
2011-01-24,Phase 1 Results Of ARQ 197 C-MET Inhibitor In Colorectal Cancer Presented At ASCO 2011 Gastrointestinal Cancers Symposium
2011-01-20,ArQule Prices Public Offering Of Common Stock
2011-01-19,ArQule Announces Proposed Public Offering
2011-01-12,Daiichi Sankyo And ArQule Enroll First Non-Small Cell Lung Cancer Patient Into Global Phase 3 Trial For ARQ 197
2010-12-06,ArQule Enrolls First Patient In Phase 1 Trial Of ARQ 736, Its Pan-RAF Inhibitor
2010-11-10,ArQule, Inc. To Present At Lazard Capital Markets 7th Annual Healthcare Conference
2010-11-09,ArQule Announces Third Quarter Fiscal 2010 Results
2010-11-03,ArQule To Report Third Quarter 2010 Financial Results On November 9, 2010
2010-11-02,ArQule Awarded $978,000 In Grants Under The Patient Protection And Affordable Care Act
2010-10-26,ArQule, Inc. To Present At Oppenheimer 21st Annual Healthcare Conference
2010-10-12,ArQule And Daiichi Sankyo Expand Drug Discovery Collaboration In Oncology
